Beneficial effect of Gyejibokryeong-hwan on climacteric syndrome with blood stasis pattern: A randomized, double-blinded, placebo-controlled clinical pilot trial.
Climacteric syndrome
Guizhifulingwan
Gyejibokryeong-hwan
Keishibukuryogan
Menopause
Journal
Integrative medicine research
ISSN: 2213-4220
Titre abrégé: Integr Med Res
Pays: Netherlands
ID NLM: 101612707
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
07
11
2022
revised:
16
04
2023
accepted:
19
04
2023
medline:
16
5
2023
pubmed:
16
5
2023
entrez:
15
5
2023
Statut:
ppublish
Résumé
Gyejibokryeong-hwan (GBH), a herbal mixture that is widely used for climacteric syndrome, is studied for its efficacy; however, no study evaluated the GBH indication, which is a blood-stasis pattern based on traditional Chinese medicine theory. This is a randomized, double-blinded, placebo-controlled clinical pilot trial. Fifty subjects with climacteric syndrome were recruited and randomly assigned to GBH group or placebo group. Subjects were administered GBH or placebo granules for 4 weeks followed by 4 weeks of observation period. For the primary outcome, the Menopause Rating Scale (MRS) was evaluated. For the secondary outcomes, quality of life, degrees of abdominal resistance and tenderness, blood-stasis pattern questionnaire and degree of upward movement of After 4-week intervention, the mean change of total MRS score significantly decreased in the GBH group compared to the placebo group ( Our findings provide evidence of the feasibility of recruiting subjects with GBH indications and show that GBH may have clinical efficacy for the treatment of menopausal symptoms, especially urogenital symptoms, without any significant adverse events. Clinical Research Information Service (CRIS identifier: KCT0002170).
Sections du résumé
Background
UNASSIGNED
Gyejibokryeong-hwan (GBH), a herbal mixture that is widely used for climacteric syndrome, is studied for its efficacy; however, no study evaluated the GBH indication, which is a blood-stasis pattern based on traditional Chinese medicine theory.
Methods
UNASSIGNED
This is a randomized, double-blinded, placebo-controlled clinical pilot trial. Fifty subjects with climacteric syndrome were recruited and randomly assigned to GBH group or placebo group. Subjects were administered GBH or placebo granules for 4 weeks followed by 4 weeks of observation period. For the primary outcome, the Menopause Rating Scale (MRS) was evaluated. For the secondary outcomes, quality of life, degrees of abdominal resistance and tenderness, blood-stasis pattern questionnaire and degree of upward movement of
Results
UNASSIGNED
After 4-week intervention, the mean change of total MRS score significantly decreased in the GBH group compared to the placebo group (
Conclusion
UNASSIGNED
Our findings provide evidence of the feasibility of recruiting subjects with GBH indications and show that GBH may have clinical efficacy for the treatment of menopausal symptoms, especially urogenital symptoms, without any significant adverse events.
Trial registration
UNASSIGNED
Clinical Research Information Service (CRIS identifier: KCT0002170).
Identifiants
pubmed: 37187679
doi: 10.1016/j.imr.2023.100951
pii: S2213-4220(23)00030-6
pmc: PMC10176163
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100951Informations de copyright
© 2023 Korea Institute of Oriental Medicine. Published by Elsevier B.V.
Références
Evid Based Complement Alternat Med. 2015;2015:316872
pubmed: 25821483
Ann Rehabil Med. 2013 Aug;37(4):488-97
pubmed: 24020029
Health Qual Life Outcomes. 2004 Sep 02;2:45
pubmed: 15345062
Menopause. 2008 Sep-Oct;15(5):1029; author reply 1029
pubmed: 18792428
BMC Complement Altern Med. 2018 Mar 23;18(1):107
pubmed: 29566679
Menopause. 2011 Aug;18(8):886-92
pubmed: 21738077
Health Qual Life Outcomes. 2004 Nov 22;2:67
pubmed: 15555079
JAMA. 2003 Jun 25;289(24):3243-53
pubmed: 12824205
Climacteric. 2000 Mar;3(1):59-64
pubmed: 11910611
Soc Sci Med. 2001 Feb;52(3):345-56
pubmed: 11330770
Ann Intern Med. 2002 May 7;136(9):680-90
pubmed: 11992304
Menopause. 2011 Jan;18(1):85-92
pubmed: 20647958
Trials. 2017 Mar 21;18(1):135
pubmed: 28327172
Menopause. 2017 Jul;24(7):728-753
pubmed: 28650869
Integr Med Res. 2021 Sep;10(3):100715
pubmed: 33665100
Maturitas. 1996 Mar;23(2):137-45
pubmed: 8735352
BMJ. 2005 Feb 12;330(7487):342
pubmed: 15640250
Chin J Integr Med. 2014 Jul;20(7):483-9
pubmed: 24610412
Arch Gynecol Obstet. 2011 Oct;284(4):913-21
pubmed: 21120510
J Ethnopharmacol. 2013 Dec 12;150(3):1114-8
pubmed: 24184192
JAMA. 2015 Nov 10;314(18):1966-7
pubmed: 26547468
JAMA. 2003 May 28;289(20):2651-62
pubmed: 12771112
Evid Based Complement Alternat Med. 2017;2017:8049481
pubmed: 29085435